1) Minoshima S, Frey KA, Koeppe RA, et al:A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 36:1238-1248, 1995
2) Blennow K, de Leon MJ, Zetterberg H:Alzheimer's disease. Lancet 368:387-403, 2006
3) Nordberg A:PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 3:519-527, 2004
4) Klunk WE, Engler H, Nordberg A, et al:Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319, 2004
5) Lopresti BJ, Klunk WE, Mathis CA, et al:Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies:a comparative analysis. J Nucl Med 46:1959-1972, 2005
6) Silverman DH:Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias:comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 45:594-607, 2004
7) Petersen RC:Mild cognitive impairment as a diagnostic entity. J Int Med 256:183-194, 2004
8) Hirao K, Ohnishi T, Hirata Y, et al:The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage 28:1014-1021, 2005
9) Drzezga A, Grimmer T, Riemenschneider M, et al:Prediction of individual clinical outcome in MCI by means of genetic assessment and(18)F-FDG PET. J Nucl Med 46:1625-1632, 2005